WALNUT CREEK and SAN DIEGO, CA / ACCESSWIRE / October 17, 2016 / Accurexa Inc. ("Accurexa") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today a collaboration with StemImmune Inc. ("StemImmune") to develop its stem cell-mediated immunotherapy for the treatment of cancer, such as brain cancer. StemImmune's immunotherapy uses the stealth anti-cancer payload carrying and tumor seeking capacities of a patient's own readily available (adult) stem cells to target cancer. The patient's immune system cannot recognize and react to the "Trojan Horse" stem cells, because they are the patient's own. To date, StemImmune has treated 25 cancer patients with its proprietary technology in a Phase 1 clinical trial that showed that its stem cell-mediated immunotherapy was safe and well-tolerated with no adverse events reported, and demonstrated potential anti-tumor activity which supports further investigation in clinical trials. All patients received treatment through a minimally invasive outpatient procedure.

"We are excited to collaborate with StemImmune and to use stem cells for the delivery of immunotherapies. Stem cells have the capacity to home to tumors, and efficiently carry proprietary anti-cancer payloads directly to cancer cells, while mobilizing the patient's immune system to recognize and fight the cancer. This approach is in line with the mission of Accurexa to directly deliver therapies to targeted areas in the treatment of cancer and other disorders, and adds a clinical-stage oncology program to our pipeline," said George Yu, MD, President & CEO of Accurexa.

"Eradicating cancer and giving patients the ability to undergo lifesaving treatment with no debilitating side effects is what drives our research. Combining our patented technology with Accurexa's proprietary methods of delivering targeted therapies to specific areas of the brain makes Accurexa a valuable partner for us as we pursue the eradication of cancer," said Aladar Szalay, PhD, Founder, CEO and Chairman of StemImmune. "We look forward to a long and productive relationship with Accurexa."

Accurexa is focused on developing novel neurological therapies to be directly delivered into specific regions of the brain. It is developing its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU, both chemotherapeutics, to brain tumor sites. Oral temozolomide is a generic, FDA approved, first-line chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before oral temozolomide became generic, it generated US sales of approximately $420 million and global sales of approximately $910 million under its brand name Temodar® in 2012. However, current standard of care of delivering temozolomide to tumor sites through oral administration is limited by the blood-brain-barrier and oral temozolomide increases patient survival by 2.5 months from a 12.1 months median overall survival. Additional information about Accurexa may be found on its website, www.accurexa.com.

StemImmune is a privately-held, clinical-stage company that has pioneered a new method of attacking some of today's most difficult to treat cancers. StemImmune's patented technology and delivery methodology leverages a patient's own stem cells, combined with a proprietary anti-cancer payload, which travel like a Trojan horse unrecognized by the patient's immune system, to deliver the potent cancer treatment directly to the tumor cells, while sparing the patient's healthy cells. This also kick starts the patient's immune system to begin fighting the cancer. The StemImmune platform has the potential to revolutionize the way that cancer is treated. StemImmune was founded in 2014 by Aladar Szalay, PhD, who is internationally recognized for his transformative research and discoveries utilizing live microorganisms (such as bacteria and viruses) to locate (diagnose) and eliminate (treat) human cancers. He founded Genelux Corporation in 2001, and served as its Chairman, President, CSO & CEO from 2001 until 2014. Under Dr. Szalay's leadership, the company's groundbreaking discovery and clinical research program yielded four Phase 1 human trials in which 80 cancer patients received the experimental drug GL-ONC1 for cancer therapy and diagnosis. Dr. Szalay is a full Professor in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center, at the University of California, San Diego, and a Professor at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine, and the Department of Biochemistry at the University of Würzburg (Germany). He has published over 225 scientific papers, and holds more than 100 issued patents and patent applications. Additional information can be found at the company's website: www.stemimmuneinc.com. Patients interested in learning more about participating in one of StemImmune's ongoing clinical trials may learn more by emailing [email protected].

This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the ability of the Company to successfully collaborate with StemImmune, develop and commercialize novel neurological therapies and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.